379 related articles for article (PubMed ID: 25414121)
1. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
Carris NW; Taylor JR; Gums JG
Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121
[TBL] [Abstract][Full Text] [Related]
2. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.
Cohen O; Filetti S; Castañeda J; Maranghi M; Glandt M
Diabetes Care; 2016 Aug; 39 Suppl 2():S180-6. PubMed ID: 27440831
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
Huthmacher JA; Meier JJ; Nauck MA
Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
[TBL] [Abstract][Full Text] [Related]
4. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
Lane W; Weinrib S; Rappaport J
Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
[TBL] [Abstract][Full Text] [Related]
5. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.
Balena R; Hensley IE; Miller S; Barnett AH
Diabetes Obes Metab; 2013 Jun; 15(6):485-502. PubMed ID: 23061470
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
[TBL] [Abstract][Full Text] [Related]
8. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
9. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
Rosenstock J; Nino A; Soffer J; Erskine L; Acusta A; Dole J; Carr MC; Mallory J; Home P
Diabetes Care; 2020 Oct; 43(10):2509-2518. PubMed ID: 32694215
[TBL] [Abstract][Full Text] [Related]
10. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.
Blonde L; Anderson JE; Chava P; Dendy JA
Curr Med Res Opin; 2019 May; 35(5):793-804. PubMed ID: 30370783
[TBL] [Abstract][Full Text] [Related]
11. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Shaefer CF; Kushner P; Aguilar R
Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
[TBL] [Abstract][Full Text] [Related]
13. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting.
Digenio A; Karve S; Candrilli SD; Dalal M
Postgrad Med; 2014 Oct; 126(6):49-59. PubMed ID: 25414934
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.
Cimmaruta D; Maiorino MI; Scavone C; Sportiello L; Rossi F; Giugliano D; Esposito K; Capuano A
Expert Opin Drug Saf; 2016 Dec; 15(sup2):77-83. PubMed ID: 27875915
[TBL] [Abstract][Full Text] [Related]
15. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
Davies ML; Pham DQ; Drab SR
Pharmacotherapy; 2016 Aug; 36(8):893-905. PubMed ID: 27340935
[TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin.
Hopton OM; Waterbury NV; Egge JA; Lund BC
Pharmacotherapy; 2022 Jan; 42(1):45-52. PubMed ID: 34807465
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
Eng C; Kramer CK; Zinman B; Retnakaran R
Lancet; 2014 Dec; 384(9961):2228-34. PubMed ID: 25220191
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
20. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
